Israel - English - Ministry of Health

takeda israel ltd - dexlansoprazole - modified release capsules - dexlansoprazole 30 mg - dexlansoprazole - dexilant 30 is indicated in adults and in adolescents aged 12 to 17 years for the following:• maintenance of healed erosive reflux oesophagitis and maintenance of relief of heartburn• short-term treatment of heartburn and acid regurgitation associated with symptomatic non-erosive gastro-oesophageal reflux disease (gord).

Israel - English - Ministry of Health

takeda israel ltd - dexlansoprazole - modified release capsules - dexlansoprazole 60 mg - dexlansoprazole - dexilant 60 is indicated in adults and in adolescents aged 12 to 17 years for the following:• treatment of erosive reflux oesophagitis

Australia - English - Department of Health (Therapeutic Goods Administration)

takeda pharmaceuticals australia pty ltd - mesalazine, quantity: 1200 mg - tablet, modified release - excipient ingredients: methacrylic acid copolymer; purified talc; silicon dioxide; sodium starch glycollate; stearic acid; iron oxide red; carmellose sodium; carnauba wax; magnesium stearate; titanium dioxide; macrogol 6000; triethyl citrate - for the induction and maintenance of remission in patients with mild to moderate, active ulcerative colitis.

Israel - English - Ministry of Health

takeda israel ltd - dexlansoprazole - modified release capsules - dexlansoprazole 30 mg - dexlansoprazole - dexilant 30 is indicated in adults and in adolescents aged 12 to 17 years for the following:• maintenance of healed erosive reflux oesophagitis and maintenance of relief of heartburn• short-term treatment of heartburn and acid regurgitation associated with symptomatic non-erosive gastro-oesophageal reflux disease (gord).

Israel - English - Ministry of Health

takeda israel ltd - dexlansoprazole - modified release capsules - dexlansoprazole 60 mg - dexlansoprazole - dexilant 60 is indicated in adults and in adolescents aged 12 to 17 years for the following:• treatment of erosive reflux oesophagitis

Israel - English - Ministry of Health

takeda israel ltd - human normal immunoglobulin - solution for infusion - human normal immunoglobulin 100 mg / 1 ml - immunoglobulins, normal human, for intravascular adm. - replacement therapy in adults, children and adolescents (0-18 years) in:• primary immunodeficiency syndromes with impaired antibody production • hypogammaglobulinaemia and recurrent bacterial infections in patients with chronic lymphocytic leukaemia (cll), in whom prophylactic antibiotics have failed or are contra-indicated.• hypogammaglobulinaemia and recurrent bacterial infections in multiple myeloma (mm) patients.• hypogammaglobulinaemia in patients pre- and post-allogeneic hematopoietic stem cell transplantation (hsct).

Israel - English - Ministry of Health

takeda israel ltd - lanadelumab - solution for injection - lanadelumab 150 mg/ml - lanadelumab - takhzyro is indicated for routine prevention of recurrent attacks of hereditary angioedema (hae)in patients aged 2 years and older.

Australia - English - Department of Health (Therapeutic Goods Administration)

takeda pharmaceuticals australia pty ltd - ixazomib citrate, quantity: 3.29 mg (equivalent: ixazomib, qty 2.3 mg) - capsule - excipient ingredients: microcrystalline cellulose; purified talc; magnesium stearate; gelatin; titanium dioxide; iron oxide red; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - ninlaro is indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

takeda pharmaceuticals australia pty ltd - ixazomib citrate, quantity: 4.3 mg (equivalent: ixazomib, qty 3 mg) - capsule - excipient ingredients: microcrystalline cellulose; purified talc; magnesium stearate; gelatin; titanium dioxide; iron oxide black; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; potassium hydroxide - ninlaro is indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

takeda pharmaceuticals australia pty ltd - ixazomib citrate, quantity: 5.7 mg (equivalent: ixazomib, qty 4 mg) - capsule - excipient ingredients: microcrystalline cellulose; purified talc; magnesium stearate; gelatin; titanium dioxide; iron oxide yellow; iron oxide red; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - ninlaro is indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy.